FIELD OF INVENTION
The present invention relates to the field of pharmaceutical chemistry.
Particularly it relates to Design, synthesis and anticancer activity studies of
some novel 1,2,4 triazole pyridine derivatives.
BACKGROUND OF INVENTION
Cancer is a deadly illness characterized by unregulated cell proliferation and
fast spread of aberrant cells. Several environmental and internal variables
contribute to aberrant cell line proliferation and the development of various
malignancies. Chemotherapy, radiation, and surgery are the three types of
cancer treatments now accessible. Chemotherapy is the conventional treatment
for cancer patients, in which various chemotherapeutic chemicals are employed
to kill cancer cells while causing little harm to normal kidney cells. Nitrogen
atoms contain heterocyclic ring moieties, which are found in both natural and
synthetic derivatives and have been shown to have powerful anticancer
properties against a variety of human are the three types of cancer treatments
now accessible. Chemotherapy is the conventional treatment for cancer
patients, in which various chemotherapeutic chemicals are employed to kill
cancer cells while causing little harm to normal kidney cells. Nitrogen atoms
contain heterocyclic ring moieties, which are found in both natural and
synthetic derivatives and have been shown to have powerful anticancer
properties against a variety of human cancer cell lines. Three nitrogen atoms
with a heterocyclic ring, such as 1,2,4-triazoles, play a vital role in the
structural elucidation of numerous natural products and can establish hydrogen
bonds with appropriate targets, increasing pharmacokinetics, pharmacological,
and toxicological aspects. Anticancer, antibacterial, antitubercular, antifungal,
antiviral, analgesic, anti-inflammatory, and tubulin inhibitor properties are all
connected with these 1,2,4-triazole compounds. Letrozol is an aromatase
inhibitor-containing triazole structural unit used to treat cancer. Researchers are
currently concentrating their efforts on developing superior, synergistic
compounds by combining two or more active biomolecules or ligands to create
novel derivatives with good pharmacological action. Triazole is an appealing
bridge group that could be used to link two pharmacophores to create novel
bifunctional compounds, despite being nearly hard to hydrolyze, oxidise, or
decrease.14 By combining the pharmacophore including 1,2,4-triazoles and
substituted benzyl groups via thio linkage, we were able to generate a small
library based on the literature data and the attributes outlined earlier. The
antitumor efficacy of a new series of 1, 2, 4-triazole-pyridine hybrid
compounds was investigated.
OBJECTS OF THE INVENTION
Some of the objects of the present disclosure, which at least one embodiment
herein satisfies, are as follows-
 It is an object of the present disclosure is to design and synthesize series of
novel 1,2,4 triazole pyridine derivatives as potential anticancer agents.
SUMMARY OF THE INVENTION
The goal of current investigation is to design and synthesize series of novel
1,2,4 triazole pyridine derivatives as potential anticancer agents.
The development of new anticancer agents is one of the most pressing research
areas in medicinal chemistry and medicine. The importance of triazole and
pyridine rings as scaffolds present in a wide range of therapeutic agents has
been well reported and has driven the synthesis of a large number of novel
anticancer agents. The presence of these heterocyclic furnishes extensive
synthetic possibilities due to the presence of several reaction sites. Prompted by
these data we designed, synthesized and evaluated a series of novel 1, 2, 4-
triazole-pyridine hybrid derivatives as potential anticancer agents.
Derivatives were synthesized by the reaction of nicotinohydrazide with carbon
disulfide to yield potassium-3-pyridyl-dithiocarbazate (I). This was further
cyclized with ammonia solution to yield 5-mercapto-substituted 1, 2, 4-
triazole-pyridine hybrid (II). This was finally reacted with different substituted
benzyl derivatives to produce 1, 2, 4-triazole-pyridine hybrid derivatives (III).
The purity of the derivatives was confirmed by thin-layer chromatography and
melting point. Structure of these derivatives was set up by determining its
infrared spectroscopy, nuclear magnetic resonance spectroscopy and mass
spectroscopy. Further, the synthesized 1, 2, 4 triazole pyridine derivatives were
tested for their in vitro anticancer activities against murine melanoma
(B16F10) using the MTT reduction assay method.
The cell viability study of synthesized compounds concludes that all
compounds have moderate to potent anticancer activities against cancer cell
lines. Compounds TP1-TP7 have IC50 in the range of 41.12µM to 61.11µM
and the highest activity was observed for compound TP6 against murine
melanoma (B16F10) cell line.
By treating pyridine linked 1,2,4-triazole-3-thiol with different substituted
benzyl halides, a new series of diverse 1,2,4-triazoles connected with
substituted benzyl groups through thio linkage derivatives was created, using a
simple, appropriate, and well-organized synthetic approach. TLC, IR, NMR,
and MS were used to confirm the physical and analytical properties of the
newly synthesized 1, 2, 4- triazole derivatives. Following that, pharmacological
testing revealed that the derivative 3-(5-(4-bromobenzylthio)-4H-1, 2, 4-
triazol-3-yl) pyridine had more anticancer activity than other compounds. As a
result, we believe that the findings of this study could open the way for the
creation of innovative anticancer drugs with high efficacy and fewer side
effects.
BRIEF DISCRIPTION OF DRAWINGS
Figure 1: Scheme for synthesis of proposed 1, 2, 4-triazole-pyridine hybrid
derivatives.

DETAILED DISCRIPTION OF INVENTION
Present invention relates to design and synthesize series of novel 1,2,4 triazole pyridine derivatives as potential anticancer agents.
Materials and Methods
All reagents and chemicals were bought for a synthetic purpose from Loba Chemie and Sigma Aldrich. The open capillary method was used to determine the melting point of the produced compounds, and the results were uncorrected. The combustion analysis was used to verify the purity of the synthesised derivatives. IR spectra (KBr, cm-1) (Perkins Elmer Infrared-283 FTIR), 1H NMR (CDCl3) spectra (Brooker 300 MHz spectrometer using tetra methyl silane as an internal reference), and mass spectra were used to validate the structure of the compounds (API 3000 LC- MS).
EXAMPLES
The present invention will hereinafter be described by the following Examples.
EXAMPLE 1
Synthesis of potassium-3-pyridyl-dithiocarbazate (I)
In 200 mL 100% ethanol, a solution of 8.4gm (0.15M) potassium hydroxide, 13.7gm (0.10M) pyridyl-2- carbohydrazide, and 11.4gm (0.15M) carbon disulfide was produced. After that, the mixture was stirred for 12-16 hours. It was then dried at 65?C after being diluted with 200 cc of dry ether. The salts were produced as stated above and yielded a practically quantitative yield, allowing them to be used without further purification.
EXAMPLE 2
Synthesis of pyridine linked 1, 2, 4-triazole-3-thiol (II)
A suspension of I (24gm, 0.096M) in 20 ml (0.864M) ammonia and 40 ml water was refluxed for 3 to 4 hours with stirring. The mixture was then placed into ice cold water (100 ml). The white precipitate was obtained and acidified with strong HCl before being filtered and rinsed in cold water.
EXAMPLE 3
Synthesis of 1, 2, 4-triazoles linked with substituted benzyl groups through thio linkage (III)
A solution of sodium (0.14gm, 6M) in dry methanol was mixed with II (0.006M), (0.69gm, 6M) in dry N, N-dimethyl formamide. The benzyl halide (6M) was added after 10 minutes of stirring at room temperature. The resulting suspension was stirred at room temperature for 1-23 hours with a CaCl2 guar tube. TLC was used to confirm the reaction’s completion, and the resulting solution was then poured onto crushed ice.
Figure 1: Scheme for synthesis of proposed 1, 2, 4-triazole-pyridine hybrid derivatives
EXAMPLE 4
Anticancer activity Screening
MTT assay
Each well of the first plate had the test ingredients removed. Then 50l of MTT reagent (5 mg/ml) was added and incubated in the CO2 incubator for 2 hours at 37?C. After that, the MTT solution was removed and 100 litres of isopropanol were added. To dissolve the formations of purple crystal formazan, the plates were shaken. A microplate reader was used to measure the absorbance at a wavelength of 570nm. Cell viability assay method was used to test the anticancer activities of several produced 1, 2, 4 triazole pyridine derivatives chemicals in vitro. 15 Murine melanoma (B16F10) cancer cell lines were employed to investigate in vitro anticancer activities. The National Center for Cell Science in Pune provided cancer cell lines. The cells were plated or cultured for 24 hours in 96-multiwell plates (104 cells/well). Before being tested for anti-cancerous properties, all of the produced compounds were dissolved in dimethyl sulphoxide. All of the chemicals were applied to the cell monolayer in various concentrations. The vitality of the cells was tested in triplicate for 48 hours using the MTT assay in two distinct dosages of the
produced compounds (100M and 10M).
Table 3: In vitro anticancer activity (IC50) of the synthesized compounds against cancer cell lines
The MTT (3-(4, 5- dimethylthiazol-2-yl) 2, 5 diphenyl tetrazolium bromide) assay was used to determine the vitality of the cells. This assay employed MTT reagent [3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyl tetrazolium bromide] at a concentration of 5 mg/ml. The anticancer efficacy of these drugs was determined using the IC50 method (the concentration that causes a 50 percent reduction of the cell growth). We created a pool of compounds with a combined pharmacophore of 1, 2, 4-triazoles and substituted benzyl groups in the quest for new anticancer drugs. TLC, combustion analysis, and different spectroscopic techniques were used to examine the newly synthesised fused pharmacophore. The MTT test method was used to assess the anticancer activity of the new compounds. Figure 1 shows the methodologies for synthesising unique merging pharmacophores of 1, 2, 4-triazoles and
substituted benzyl groups. By treating 5-mercapto-3-pyridyl-1, 2, 4-triazole with variously substituted benzyl halides, a pool of seven distinct merging pharmacophores was created. Table 1 Displayed the chemical structure, melting point, and other physical data, whereas Table 2 displayed the results of the combustion analysis. The IR, 1H NMR, and MS spectrum of several 1,2,4-triazoles coupled with substituted benzyl groups via thio linkage derivatives were recorded to demonstrate their formation. The infrared spectra of 3-(5-(4-chlorobenzylthio)-4H-1,2,4-triazol-3-yl) pyridine, a 1,2,4-triazole derivative, displayed a strong C=N stretching (str) band at 1595.76 cm-1 and a C-N absorption band at 1252.41 cm-1, indicating ring closure of the 1,2,4-triazole ring. Aromatic (Ar) C-H str has an absorption band at 2978.85 cm-1, C=C str has an absorption band at 1630.41 cm-1, C-Cl str has an absorption band at 735.83 cm-1, and C-S str has an absorption band at 657.11 cm-1. All derivatives had strong absorption at roughly 3078.85 and 1620.47 cm-1, which was confirmed for aromatic C-H and C=C bonds, respectively. 1H NMR results revealed the existence of certain functional groups in produced derivatives. The four aromatic proton, 7.40-8.90 is due to four pyridine proton, and 4.25 is due to two methylene proton in the 1H NMR spectrum of triazole derivatives 3-(5-(4-chlorobenzylthio)-4H-1,2,4-triazol-3-yl) pyridine. Shift value 3.67 confirmed the presence of another group, such as -CH3 manufactured derivatives. The mass spectra of the triazole derivative 3-(5-(4-chlorobenzylthio)-4H- 1,2,4-triazol-3-yl) pyridine revealed a molecular ion peak at m/z 301+, which matches the molecular formula C14H11ClN4S. Table 3 also contains spectral data for the remaining derivatives. The MTT assay was used to investigate the in vitro anticancer properties of the synthesized 1, 2, 4 triazole pyridine derivatives against murine melanoma (B16F10). Table 3 summarizes the assay results given as IC50 (M). The IC50 value is the average of three separate experiments and indicates the concentration of a substance that inhibits cell growth by 50% after 48 hours of incubation. Because the results indicate that all of the tested compounds have potential, they were chosen for the measurement of IC50 values, or the concentration required inhibiting cancer cells by 50% when treated with manufactured compounds. According to the results of the cell viability research, all produced compounds have moderate to powerful anticancer activity against cancer cell lines. Compounds TP1-TP7 exhibit IC50s ranging from 41.12M to 61.11M, with compound TP6 having the highest activity against the murine melanoma (B16F10) cell line.

We claim,

Claim 1: A compound selected from the group of compounds represented by Formula (I)
Claim 2: A compound according to claim 1 wherein the said compound was synthesized by treating pyridine linked 1,2,4-triazole-3-thiol with different substituted benzyl halides.
Claim 3: A compound according to claim 1 wherein the said compound contains 1,2,4-triazoles connected with substituted benzyl groups through thio linkage derivatives.
Claim4: A compound according to claim 1 wherein derivative 3-(5-(4-bromobenzylthio)-4H-1, 2, 4- triazol-3-yl) pyridine had more anticancer activity than other compounds.
Claim5: A compound as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable derivative thereof, for use in the treatment of cancer condition or disease state.